syva PRESS RELEASE

VMD grants marketing authorisation for Syvazul® BTV3 in Great Britain

Syvazul® BTV 3 has been granted a marketing authorisation in Great Britain for use in cattle and sheep, with a reduced dose in cattle.

León, 9 July 2025 – Syva is pleased to announce that **Syvazul® BTV 3 has been granted a marketing authorisation (Vm 31592/5006) in GB**, allowing its use **in cattle and sheep** to combat **Bluetongue virus serotype 3 (BTV-3)**. The authorisation, effective from **3 July 2025**, is **valid indefinitely**.

A major update for cattle: reduced dose

A key breakthrough in this new authorisation is that **the dose for cattle has been reduced from 4 ml to 2 ml**, improving convenience and aligning with the latest regulatory data.

Reminder Indications and administration

-> Cattle

- For active immunisation to reduce viraemia caused by BTV-3.
- **Onset of immunity**: 3 weeks after completing the primary vaccination course.

Dosage (intramuscular):

- From 2 months of age in naïve animals, or from 3 months if born to immune dams.
- **Primary vaccination**: 2 doses of 2 ml, 3 weeks apart.

-> Sheep

- For active immunisation to reduce viraemia, mortality, clinical signs and lesions caused by BTV-3.
- **Onset of immunity**: 4 weeks after completing the primary vaccination course.

Dosage (subcutaneous):

- From 3 months of age.
- **Primary vaccination**: 1 single dose of 2 ml.